[go: up one dir, main page]

WO2017222252A1 - Composition pharmaceutique pour la prévention ou le traitement du cancer du côlon, contenant un extrait de telectadium dongnaiense comme principe actif - Google Patents

Composition pharmaceutique pour la prévention ou le traitement du cancer du côlon, contenant un extrait de telectadium dongnaiense comme principe actif Download PDF

Info

Publication number
WO2017222252A1
WO2017222252A1 PCT/KR2017/006376 KR2017006376W WO2017222252A1 WO 2017222252 A1 WO2017222252 A1 WO 2017222252A1 KR 2017006376 W KR2017006376 W KR 2017006376W WO 2017222252 A1 WO2017222252 A1 WO 2017222252A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
colorectal cancer
wnt
catenin
signaling system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2017/006376
Other languages
English (en)
Korean (ko)
Inventor
이상국
박헌주
김원경
바이트 트란더
하이 도반
꽝 부이홍
엄상미
최상호
이상우
이창영
이중구
박상홍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Korea Research Institute of Bioscience and Biotechnology KRIBB
SNU R&DB Foundation
Original Assignee
Korea Research Institute of Bioscience and Biotechnology KRIBB
Seoul National University R&DB Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020170076747A external-priority patent/KR101926021B1/ko
Application filed by Korea Research Institute of Bioscience and Biotechnology KRIBB, Seoul National University R&DB Foundation filed Critical Korea Research Institute of Bioscience and Biotechnology KRIBB
Publication of WO2017222252A1 publication Critical patent/WO2017222252A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/24—Apocynaceae (Dogbane family), e.g. plumeria or periwinkle

Definitions

  • Extract according to the present invention can effectively inhibit the proliferation of colorectal cancer cells by inhibiting the Wnt / ⁇ -catenin signaling system or pathway, and verified the effect on various transcription factors involved in the Wnt / ⁇ -catenin signaling system .
  • Colorectal cancer according to the present application is particularly colorectal cancer in which the Wnt / ⁇ -catenin signaling system is overactivated. Whether the Wnt / ⁇ -catenin signaling system is overactivated is referred to, for example, the constituents constituting the Wnt / ⁇ -catenin signaling system with reference to the contents described herein and the documents described herein. Can be determined by measuring the expression of genes and proteins, or by measuring the mutations of genes and proteins, and comparing them with corresponding measurements in appropriate controls such as normal colon cells.
  • Figure 5 shows the concentration-dependent effect on the expression of c-Myc, Cyclin D1 and Survivin proteins, which are sub-regulators of Wnt / ⁇ -catenin signaling by the Telectium dongnae extract in colorectal cancer cell line (HCT116). This indicates that the lectrectium dongnae extract according to the present application inhibits the proliferation of colorectal cancer through the inhibition of the Wnt / ⁇ -catenin signaling system.
  • the present application relates to a pharmaceutical composition for preventing and treating colorectal cancer, which contains as an active ingredient telerectium dongnae extract.
  • the "individual" means all animals including humans who may develop or may develop cancer, and by administering the anticancer adjuvant of the present invention to an individual, the cancer may be effectively treated while minimizing side effects of the anticancer agent.
  • the anticancer adjuvant of the present invention can be administered to a human suffering from colorectal cancer who is receiving an anticancer agent to effectively treat cancer while reducing side effects of anticancer.
  • composition ratio is a composition that is relatively suitable for the preferred beverage in a preferred embodiment
  • compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medical Informatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique et un aliment fonctionnel pour la santé, destinés à la prévention et au traitement du cancer du côlon et contenant un extrait de Telectadium dongnaiense comme principe actif. L'extrait cible la voie de signalisation Wnt/β-caténine, pouvant de ce fait être utilisé comme traitement de cancers provoqués par une anomalie de la voie de signalisation Wnt ou comme un adjuvant anticancéreux.
PCT/KR2017/006376 2016-06-21 2017-06-19 Composition pharmaceutique pour la prévention ou le traitement du cancer du côlon, contenant un extrait de telectadium dongnaiense comme principe actif Ceased WO2017222252A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR20160077277 2016-06-21
KR10-2016-0077277 2016-06-21
KR10-2017-0076747 2017-06-16
KR1020170076747A KR101926021B1 (ko) 2016-06-21 2017-06-16 텔렉타디엄 동나이엔스 추출물을 유효성분으로 하는 대장암 예방 또는 치료용 약학 조성물

Publications (1)

Publication Number Publication Date
WO2017222252A1 true WO2017222252A1 (fr) 2017-12-28

Family

ID=60784877

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/006376 Ceased WO2017222252A1 (fr) 2016-06-21 2017-06-19 Composition pharmaceutique pour la prévention ou le traitement du cancer du côlon, contenant un extrait de telectadium dongnaiense comme principe actif

Country Status (1)

Country Link
WO (1) WO2017222252A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030016774A (ko) * 2001-08-21 2003-03-03 (주)허벤텍 안토파인을 포함하는 조성물 및 그 용도
KR20080014326A (ko) * 2006-08-10 2008-02-14 인제대학교 산학협력단 대장암 예방 및 치료에 사용되는 해조류 추출물 및 그제조방법
WO2014128142A1 (fr) * 2013-02-19 2014-08-28 Deutsches Krebsforschungszentrum Signature de la signalisation wnt/ss-caténine dans le cancer
KR20150037024A (ko) * 2013-09-30 2015-04-08 서울대학교산학협력단 가중나무 추출물을 유효성분으로 하는 암질환의 치료 또는 예방용 조성물

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030016774A (ko) * 2001-08-21 2003-03-03 (주)허벤텍 안토파인을 포함하는 조성물 및 그 용도
KR20080014326A (ko) * 2006-08-10 2008-02-14 인제대학교 산학협력단 대장암 예방 및 치료에 사용되는 해조류 추출물 및 그제조방법
WO2014128142A1 (fr) * 2013-02-19 2014-08-28 Deutsches Krebsforschungszentrum Signature de la signalisation wnt/ss-caténine dans le cancer
KR20150037024A (ko) * 2013-09-30 2015-04-08 서울대학교산학협력단 가중나무 추출물을 유효성분으로 하는 암질환의 치료 또는 예방용 조성물

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHOI SO JIN ET AL.: "Screening of herbal medicines from Vietnam with inhibitory activity on advanced glycation end products formation", KOREAN JOURNAL OF PHARMACOGNOSY, vol. 46, no. 3, 2015, pages 268 - 278, XP053034980 *
KIM, WK: "Antitumor activity of periplocin, isolated from Telectadium dongnaiense, in colorectal cancer cells via suppression of Wnt/beta-catenin signaling", PLANTA MEDICA, vol. 82, no. s01, 14 December 2016 (2016-12-14), XP055601289, DOI: 10.1055/s-0036-1596587 *
KIM, WON KYUNG: "P7-26) Antiproliferative activity of Telectadium dongnaiense and its constituents via inhibition of the Wnt/13-catenin signaling in human colon cancer cells", INTERNATIONAL CONFERENCE ON 70TH ANNIVERSARY OF THE PHARMACEUTICAL SOCIETY OF KOREA, 18 October 2016 (2016-10-18) - 20 October 2016 (2016-10-20), Seoul *

Similar Documents

Publication Publication Date Title
WO2015130109A1 (fr) Composition pharmaceutique pour le traitement du cancer contenant du gossypol et de la phénformine en tant que principes actifs
WO2017039365A1 (fr) Méthode d'inhibition de l'absorption et/ou de promotion de l'excrétion de lipides à l'aide de d-psicose
WO2014065545A1 (fr) Composition pharmaceutique contenant de la lobarstine pour prévenir ou traiter une tumeur cérébrale et polythérapie pour le traitement d'une tumeur cérébrale l'utilisant
WO2017014502A1 (fr) Composition pharmaceutique pour la prévention ou le traitement de maladies médiées par il-6 comprenant un extrait de fleur de rosa rugosa en tant que substance active
WO2020122391A1 (fr) Composition pour la prévention ou le traitement de maladies associées à la sénescence cellulaire, contenant de l'homoharringtonine en tant que principe actif
WO2017078405A1 (fr) Composition pharmaceutique pour le traitement du cancer du poumon comprenant un composé à base de glucocorticoïde
WO2018106002A1 (fr) Composition pour la prévention et le traitement de la stérilité masculine, contenant une combinaison de composés comprenant un dérivé de flavonoïde et un dérivé d'iridoïde à titre de principe actif, et son utilisation
KR101545507B1 (ko) 가중나무 추출물을 유효성분으로 하는 암질환의 치료 또는 예방용 조성물
WO2019221453A1 (fr) Composition comprenant un composé tussilagone isolé à partir d'un extrait de tussilago farfara l. pour la prévention et le traitement du cancer et son utilisation
WO2014051359A1 (fr) Composition pharmaceutique comprenant de la néférine comme ingrédient actif de prévention contre un hépatome ou de traitement de ce dernier
WO2011008052A2 (fr) Composition pour la prévention ou le traitement de maladies osseuses comprenant du daropate de colforsine
WO2013062247A2 (fr) Composé diterpène de type phorbol, et composition pharmaceutique pour le traitement ou la prévention de maladies infectieuses virales le comprenant
WO2016190481A1 (fr) Adjuvant anticancéreux contenant un composé de ginsenocide de panaxadiol
WO2020032452A1 (fr) Composition comprenant un composé à base d'or en tant que principe actif visant à inhiber la différenciation des ostéoclastes
WO2017142269A1 (fr) Nouveau dérivé indole et composition anticancéreuse contenant ce dernier
WO2017222252A1 (fr) Composition pharmaceutique pour la prévention ou le traitement du cancer du côlon, contenant un extrait de telectadium dongnaiense comme principe actif
WO2014168458A1 (fr) Utilisation de composés isolés à partir de l'écorce de mûrier
WO2023008981A1 (fr) Composition antivirale et son utilisation
WO2019078381A1 (fr) Composition pharmaceutique, composition alimentaire et additif alimentaire pour prévenir, soulager ou traiter la perte, la faiblesse et l'atrophie musculaires, contenant, à titre de principe actif, une bactérie enterococcus faecalis, le liquide de culture ou des cellules mortes de celle-ci
WO2018105998A1 (fr) Composition destinée à la prévention et au traitement de l'infertilité masculine, comprenant un composé dérivé de flavonoïdes en tant que principe actif, et son utilisation
WO2022270760A1 (fr) Méthode de traitement de la stéatohépatite non alcoolique par la co-administration d'un dérivé de la curcumine et d'un inhibiteur du récepteur de tgf-β
WO2022025709A1 (fr) Utilisation préventive, de soulagement ou thérapeutique de composé thiophène 2,3,5-substitué contre une tumeur stromale gastro-intestinale
WO2021054637A1 (fr) Composition pour la prévention, l'amélioration ou le traitement d'une maladie dégénérative du cerveau, comprenant un extrait de periostracum cicadae
WO2019245245A1 (fr) Composition pharmaceutique pour la prévention et le traitement d'une lésion hépatique comprenant un extrait de curcuma
KR20210004133A (ko) 장수풍뎅이 유충 추출물 또는 분말의 유효성분을 포함하는 지방간 예방 및 치료용 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17815665

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17815665

Country of ref document: EP

Kind code of ref document: A1